Table 1 Reports and patients characteristics.
Report characteristics | |
Report type, n (%) | |
Phase I | 16 (42) |
Phase I/II | 12 (31) |
Phase II | 6 (16) |
Retrospective | 1 (3) |
Real world | 3 (8) |
Report location, n (%) | |
Asia | 15 (39) |
Europe | 4 (11) |
North America | 14 (37) |
Other | 5 (13) |
Number of centers, median (range) | 1 (1–73) |
Survival curves, n (%) | |
Yes | 25 (67) |
No | 13 (33) |
CRS Scale used, n (%) | |
ASTCT | 5 (13) |
Lee | 18 (47) |
MSKCC | 2 (5) |
Penn | 7 (19) |
Unreported | 6 (16) |
CAR design | |
Vector type, n % | |
Lentivirus | 26 (68) |
Retrovirus | 7 (18) |
Other | 1 (3) |
Unreported | 4 (11) |
Costimulatory domain, n % | |
4-1BB | 27 (71) |
CD28 | 5 (13) |
CD28/4-1BB | 4 (11) |
Unreported | 2 (5) |
CAR Hinge, n % | |
CD28 | 5 (13) |
CD8 | 18 (47) |
IgG4 | 2 (5) |
Unreported | 13 (34) |
CAR scFV Clone, n % | |
A3B1 | 1 (3) |
CAT13.1E10 | 2 (5) |
FMC63 | 21 (55) |
HI19α | 1 (3) |
Unreported | 13 (34) |
Patient characteristics | |
Patients Enrolled, n | 2134 |
Patients Infused, n | 1908 |
Age, range | 0.4–76 |
Median number of therapies, range | 2–9 |
Previous HST, % (95% CI) | 29 (23–37) |
Median blast percentage, range | 0.25–74 |
